<DOC>
	<DOCNO>NCT00699335</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety Matrifen® patient severe chronic pain could sufficiently treat opioid analgetics ( WHO class 3 ) .</brief_summary>
	<brief_title>Matrifen® Therapy Severe Chronic Pain®</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Main inclusion criterion : Outpatients severe , chronic pain Main exclusion criterion : Hypersensitivity fentanyl Coadministration monoamineoxidaseinhibitors Pregnancy Respiratory depression Chronic obstructive pulmonary disease ( COPD ) Drug abuse Impairment CNS function Other criterion define Summary Product Characteristics ( Chapter 4.3 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>fentanyl</keyword>
	<keyword>transdermal patch</keyword>
</DOC>